Navigation Links
Exosome Diagnostics Announces Additions to Management Team

NEW YORK, Sept. 3 /PRNewswire/ -- Exosome Diagnostics, Inc. today announced additions to its management team as the company moves forward with development of its blood-based diagnostics that can identify cancer-specific genetic mutations.

Wayne D. Comper, Ph.D., D.Sc., has joined Exosome Diagnostics as the chief scientific officer. Dr. Comper has extensive experience both as a biotechnology executive and as a biomedical research scientist. Prior to joining Exosome, he was chief science officer of AusAm Biotechnologies, Inc., a company developing diagnostics and therapeutics to identify and treat kidney, cardiovascular and infectious diseases. Dr. Comper has also published over 160 articles in peer-reviewed international journals. Dr. Comper received both his Ph.D. and D.Sc. from Monash University, Clayton, Victoria, Australia.

Tom Tsakeris has been appointed director of regulatory affairs. Mr. Tsakeris' expertise includes extensive experience with the Food and Drug Administration (FDA) and as an advisor to companies on the regulatory approval process. Prior to joining Exosome, Mr. Tsakeris was president of Devices and Diagnostics Consulting Group, Inc. His prior positions also include director of the Division of Clinical Laboratory Devices, Office of Device Evaluation, Center for Devices and Radiological Health and several other management roles at FDA. During his tenure at FDA, he played a key role in developing the implementation strategy for the Clinical Laboratory Improvement Act (CLIA) of 1988.

"With our exosome technology, we are able to overcome a fundamental issue of how to capture diagnostic quantities of genetic mutations in blood," said James McCullough, chairman & chief executive officer. "These mutations contain enormous amounts of information specific to different types of cancers that can be used for diagnosis and disease monitoring. These important management additions will now enable us to expand clinical development of our first blood-based genomic test for neuroblastoma, complete a partnership with a CLIA-approved clinical laboratory and launch of our first clinical diagnostic in 2009."

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary genetics-based diagnostic tests with applications in oncology and endocrinology. Exosome's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers and that they can be reliably harvested and used as a diagnostic tool for cancers and metabolic diseases. Exosome Diagnostics' lead program is a blood-based diagnostic test for the management of neuroblastoma patients. For more information, visit

Media Contacts:

Robert Flamm, Ph.D., or David Schull

Russo Partners

(212) 845-4226

SOURCE Exosome Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. Strategic Diagnostics Updates Roth Conference Presentation Time
3. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
7. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
8. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
9. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
10. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
11. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):